$RGNX
REGENXBIO Inc.

2017 Q3 Form 10-Q Financial Statement

#000156459017016550 Filed on August 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2016 Q4
Revenue $1.336M $6.562M $1.696M
YoY Change 968.8% 176.29% -61.81%
Cost Of Revenue $700.0K $6.000K $300.0K
YoY Change 3081.82% -87.76% -66.67%
Gross Profit $700.0K $6.556M $1.400M
YoY Change 579.61% 181.86% -61.11%
Gross Profit Margin 52.4% 99.91% 82.55%
Selling, General & Admin $9.400M $6.400M $5.700M
YoY Change 51.61% 3.23% 35.71%
% of Gross Profit 1342.86% 97.62% 407.14%
Research & Development $12.52M $13.92M $16.06M
YoY Change -0.33% 30.31% 233.73%
% of Gross Profit 1788.29% 212.28% 1147.07%
Depreciation & Amortization $700.0K $700.0K $200.0K
YoY Change 250.0% 600.0% 100.0%
% of Gross Profit 100.0% 10.68% 14.29%
Operating Expenses $12.52M $13.92M $16.06M
YoY Change -0.33% 30.31% 233.73%
Operating Profit -$11.82M -$15.06M -$14.66M
YoY Change -36.69% 0.7% 1109.49%
Interest Expense $600.0K $600.0K $400.0K
YoY Change 20.0% 20.0% 33.33%
% of Operating Profit
Other Income/Expense, Net $603.0K $583.0K
YoY Change 17.32% 13.2%
Pretax Income -$20.70M -$14.50M -$20.00M
YoY Change 13.74% 0.69% 284.62%
Income Tax -$400.0K
% Of Pretax Income
Net Earnings -$20.71M -$14.47M -$19.61M
YoY Change 14.06% 0.25% 278.68%
Net Earnings / Revenue -1549.85% -220.56% -1156.13%
Basic Earnings Per Share -$0.67 -$0.47
Diluted Earnings Per Share -$0.67 -$0.47 -$739.6K
COMMON SHARES
Basic Shares Outstanding 30.89M 30.66M 26.48M
Diluted Shares Outstanding 30.66M

Balance Sheet

Concept 2017 Q3 2017 Q2 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.7M $162.1M $89.60M
YoY Change 81.59% 72.08% -21.47%
Cash & Equivalents $60.11M $57.65M $24.84M
Short-Term Investments $106.8M $104.4M $64.70M
Other Short-Term Assets $4.600M $1.252M $1.010M
YoY Change 9.52% -56.83% 18.68%
Inventory
Prepaid Expenses $2.432M $1.775M
Receivables $900.0K $100.0K $1.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $172.2M $165.8M $93.37M
YoY Change 78.26% 69.37% -20.97%
LONG-TERM ASSETS
Property, Plant & Equipment $11.50M $11.52M $9.324M
YoY Change 98.28% 297.38% 1633.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $24.50M $46.40M $69.40M
YoY Change -73.68% -55.73% -32.29%
Other Assets $1.100M $393.0K $400.0K
YoY Change 120.0% -21.4% 138.1%
Total Long-Term Assets $37.10M $58.56M $79.36M
YoY Change -62.68% -45.88% -23.12%
TOTAL ASSETS
Total Short-Term Assets $172.2M $165.8M $93.37M
Total Long-Term Assets $37.10M $58.56M $79.36M
Total Assets $209.3M $224.4M $172.7M
YoY Change 6.79% 8.87% -21.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $3.948M $1.543M
YoY Change -51.85% 88.0% 52.17%
Accrued Expenses $10.80M $7.500M $8.100M
YoY Change 20.0% 5.63% 153.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.40M $11.46M $9.669M
YoY Change -6.94% 25.96% 122.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.200M $1.200M $1.300M
YoY Change -14.29% 71.43% 550.0%
Total Long-Term Liabilities $1.200M $1.200M $1.300M
YoY Change -14.29% 71.43% 550.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.40M $11.46M $9.669M
Total Long-Term Liabilities $1.200M $1.200M $1.300M
Total Liabilities $14.60M $12.68M $11.00M
YoY Change -7.01% 28.07% 140.49%
SHAREHOLDERS EQUITY
Retained Earnings -$151.1M -$114.6M
YoY Change 121.98%
Common Stock $363.4M $276.4M
YoY Change 2.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $194.7M $211.7M $161.7M
YoY Change
Total Liabilities & Shareholders Equity $209.3M $224.4M $172.7M
YoY Change 6.79% 8.87% -21.97%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2016 Q4
OPERATING ACTIVITIES
Net Income -$20.71M -$14.47M -$19.61M
YoY Change 14.06% 0.25% 278.68%
Depreciation, Depletion And Amortization $700.0K $700.0K $200.0K
YoY Change 250.0% 600.0% 100.0%
Cash From Operating Activities -$17.20M -$9.500M -$20.50M
YoY Change 45.76% 13.1% 365.91%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K -$1.700M -$4.400M
YoY Change -77.27% 54.55% 4300.0%
Acquisitions
YoY Change
Other Investing Activities $19.20M -$23.90M $21.80M
YoY Change 58.68% -712.82% -115.12%
Cash From Investing Activities $18.80M -$25.60M $17.40M
YoY Change 91.84% -982.76% -112.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 600.0K 10.80M -100.0K
YoY Change 500.0% 10700.0% -95.83%
NET CHANGE
Cash From Operating Activities -17.20M -9.500M -20.50M
Cash From Investing Activities 18.80M -25.60M 17.40M
Cash From Financing Activities 600.0K 10.80M -100.0K
Net Change In Cash 2.200M -24.30M -3.200M
YoY Change -215.79% 350.0% -97.88%
FREE CASH FLOW
Cash From Operating Activities -$17.20M -$9.500M -$20.50M
Capital Expenditures -$500.0K -$1.700M -$4.400M
Free Cash Flow -$16.70M -$7.800M -$16.10M
YoY Change 73.96% 6.85% 274.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2432000
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
64714000
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30894443
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1032000
CY2017Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
50000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-74000
rgnx Grants Revenue Expenses
GrantsRevenueExpenses
29000
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q2 rgnx Grants Revenue Expenses
GrantsRevenueExpenses
7000
CY2016Q2 rgnx Grants Revenue Expenses
GrantsRevenueExpenses
23000
rgnx Grants Revenue Expenses
GrantsRevenueExpenses
7000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
134000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
17327000
us-gaap Costs And Expenses
CostsAndExpenses
44995000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15056000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14952000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37978000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26203000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-613000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1240000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36466000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25205000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.27
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28678000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26344000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
480000
us-gaap Share Based Compensation
ShareBasedCompensation
3202000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-987000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
104000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-40000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-982000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1353000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
657000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
460000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
242000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
586000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
86000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24840000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57649000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30853000
us-gaap Costs And Expenses
CostsAndExpenses
28971000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9324000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
400000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11524000
CY2017Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
46417000
CY2016Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
69412000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37079000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23965000
us-gaap Net Income Loss
NetIncomeLoss
-25205000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1512000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
998000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
246000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-613000
CY2017Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-74000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
225000
us-gaap License Costs
LicenseCosts
1402000
us-gaap License Costs
LicenseCosts
515000
us-gaap Revenues
Revenues
2768000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
224376000
CY2016Q4 us-gaap Liabilities
Liabilities
10995000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9669000
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3948000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1775000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1543000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
363393000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
225000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
276354000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
165817000
CY2017Q2 rgnx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7514000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
393000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-646000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151053000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114587000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
211697000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
161737000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
172732000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1217000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
93371000
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q2 us-gaap Assets
Assets
224376000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1326000
CY2016Q4 us-gaap Assets
Assets
172732000
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 rgnx Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8126000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11462000
CY2017Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1252000
CY2017Q2 us-gaap Liabilities
Liabilities
12679000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1010000
CY2017Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-29000
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
49000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-14473000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
6000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
79000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6355000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30536000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6169000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10680000
CY2017Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
104434000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
107000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26477000
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30853000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26477000
CY2017Q2 us-gaap Licenses Revenue
LicensesRevenue
6555000
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
2245000
us-gaap Licenses Revenue
LicensesRevenue
2573000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
166000
CY2017Q2 us-gaap Revenues
Revenues
6562000
CY2016Q2 us-gaap Revenues
Revenues
2375000
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Revenues
Revenues
7017000
CY2017Q2 us-gaap Investment Income Net
InvestmentIncomeNet
583000
us-gaap Investment Income Net
InvestmentIncomeNet
1512000
CY2017Q2 us-gaap License Costs
LicenseCosts
1311000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
515000
CY2016Q2 us-gaap License Costs
LicenseCosts
449000
us-gaap Investment Income Net
InvestmentIncomeNet
998000
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12977000
CY2016Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
20000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
21618000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16863000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11648000
CY2016Q2 us-gaap Investment Income Net
InvestmentIncomeNet
515000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14547000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14473000
us-gaap Net Income Loss
NetIncomeLoss
-36466000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1240000
CY2016Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
246000
us-gaap Licenses Revenue
LicensesRevenue
7010000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13917000
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-14437000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14191000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14437000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30662000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26362000
us-gaap Share Based Compensation
ShareBasedCompensation
5074000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-945000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1257000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
480000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
583000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
133724000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
930000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
98000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2723000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-31000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2982000
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
-127000
rgnx Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-89000
rgnx Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
601000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27030000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16317000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
46593000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32261000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
28010000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26131000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
780000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4609000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1491000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
225000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-22412000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7846000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
329000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
130000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
147000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
81994000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
219000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
82251000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
130000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
32809000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-24033000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54116000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30083000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
939000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
193000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">REGENXBIO Inc. (the Company) is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company&#8217;s proprietary adeno-associated virus (AAV) gene delivery platform (NAV&#174; Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Company&#8217;s NAV&#174; Technology Platform is being applied by the Company, as well as by third-party licensees, in the development of product candidates for a variety of&#160;diseases with unmet needs. The Company was formed in 2008 in the state of Delaware and is headquartered in Rockville, Maryland.</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Follow-on Public Offering</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2017, the Company completed a follow-on public offering whereby the Company sold 3,700,000 shares of common stock at a price of $20.50 per share. In connection with the offering, the Company granted the underwriters an option to purchase up to 555,000 additional shares of common stock at the public offering price. The underwriters exercised the option in full and purchased the additional shares on April 26, 2017. The aggregate net proceeds received by the Company from the offering, inclusive of the underwriters&#8217; option exercise, were $81.5 million, net of underwriting discounts and commissions and offering expenses payable by the Company. </p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Risks </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2017, the Company had generated an accumulated deficit of $151.1 million since inception. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support the Company&#8217;s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional capital.<font style="color:#000000;"> As of June 30, 2017, the Company had cash, cash equivalents and marketable securities of $208.5 million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical trials, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to transition from clinical manufacturing to commercial production of products.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the consolidated financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued research and development expenses and the fair value of financial instruments.</p></div>
CY2017Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
208500000
rgnx Forfeiture Rate Used To Calculate Stock Based Compensation Expense
ForfeitureRateUsedToCalculateStockBasedCompensationExpense
0.00
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
151062000
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
229000
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
150851000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
700000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
298000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
134126000
CY2017Q2 rgnx Available For Sale Securities Remaining Maturities Greater Than Three Years
AvailableForSaleSecuritiesRemainingMaturitiesGreaterThanThreeYears
0
CY2016Q4 rgnx Available For Sale Securities Remaining Maturities Greater Than Three Years
AvailableForSaleSecuritiesRemainingMaturitiesGreaterThanThreeYears
0
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-100000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-100000
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
200000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1200000
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
127200000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
102500000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
802000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1638000
CY2016 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
45
CY2017Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
208500000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
158966000
CY2017Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13404000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9948000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1880000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
624000
CY2015Q3 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
300000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1687000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1626000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
665000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
952000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7370000
us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2016 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
rgnx Milestone Fee Payments Upon Submission Preclinical Filings
MilestoneFeePaymentsUponSubmissionPreclinicalFilings
500000
rgnx Milestone Fee Payments Upon Commencement Of Clinical Trials
MilestoneFeePaymentsUponCommencementOfClinicalTrials
29200000
rgnx Milestone Fee Payments Upon Submission Of Regulatory Approval Filings
MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings
48500000
rgnx Milestone Fee Payments Upon Approval Of Commercial Products
MilestoneFeePaymentsUponApprovalOfCommercialProducts
110500000
rgnx Milestone Fee Payments Upon Achievement Of Specified Sales Targets
MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets
92000000
CY2017Q2 rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
6000000
CY2016Q2 rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
2000000
rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
6000000
rgnx Upfront License Fee And Option Fees Revenue
UpfrontLicenseFeeAndOptionFeesRevenue
2000000
CY2017Q2 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
140000
CY2016Q2 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
80000
us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
390000
us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
330000
CY2017Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
415000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
165000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
620000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
243000
CY2017Q2 rgnx Licenses Revenue Including Amounts From Related Parties
LicensesRevenueIncludingAmountsFromRelatedParties
6555000
CY2016Q2 rgnx Licenses Revenue Including Amounts From Related Parties
LicensesRevenueIncludingAmountsFromRelatedParties
2245000
rgnx Licenses Revenue Including Amounts From Related Parties
LicensesRevenueIncludingAmountsFromRelatedParties
7010000
rgnx Licenses Revenue Including Amounts From Related Parties
LicensesRevenueIncludingAmountsFromRelatedParties
2573000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2483000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1656000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5074000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3202000
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
26000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5901000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4785000
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5901000
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4785000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3896000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3338000
CY2017Q2 rgnx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
2133000
CY2016Q4 rgnx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
3005000
CY2017Q2 rgnx Accrued External General And Administrative Expenses
AccruedExternalGeneralAndAdministrativeExpenses
943000
CY2016Q4 rgnx Accrued External General And Administrative Expenses
AccruedExternalGeneralAndAdministrativeExpenses
672000
CY2017Q2 rgnx Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
50000
CY2016Q4 rgnx Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
844000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
492000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
267000

Files In Submission

Name View Source Status
0001564590-17-016550-index-headers.html Edgar Link pending
0001564590-17-016550-index.html Edgar Link pending
0001564590-17-016550.txt Edgar Link pending
0001564590-17-016550-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201708081816110682307.jpg Edgar Link pending
g201708081816110802308.jpg Edgar Link pending
g201708081816110972309.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgnx-10q_20170630.htm Edgar Link pending
rgnx-20170630.xml Edgar Link completed
rgnx-20170630.xsd Edgar Link pending
rgnx-20170630_cal.xml Edgar Link unprocessable
rgnx-20170630_def.xml Edgar Link unprocessable
rgnx-20170630_lab.xml Edgar Link unprocessable
rgnx-20170630_pre.xml Edgar Link unprocessable
rgnx-ex101_86.htm Edgar Link pending
rgnx-ex311_9.htm Edgar Link pending
rgnx-ex312_7.htm Edgar Link pending
rgnx-ex321_6.htm Edgar Link pending
Show.js Edgar Link pending